$775 Million is the total value of Soleus Capital Management, L.P.'s 65 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LYRA | Exit | LYRA THERAPEUTICS INC | $0 | – | -10,000 | -100.0% | -0.00% | – |
| NGM | Exit | NGM BIOPHARMACEUTICALS INC | $0 | – | -13,000 | -100.0% | -0.02% | – |
| BEAM | Exit | BEAM THERAPEUTICS INC | $0 | – | -2,850 | -100.0% | -0.02% | – |
| BCYC | Exit | BICYCLE THERAPEUTICS PLCsponsored ads | $0 | – | -10,250 | -100.0% | -0.06% | – |
| HOWL | Exit | WEREWOLF THERAPEUTICS INC | $0 | – | -64,585 | -100.0% | -0.08% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -11,000 | -100.0% | -0.09% | – |
| Exit | AVALO THERAPEUTICS INC | $0 | – | -770,000 | -100.0% | -0.13% | – | |
| VNDA | Exit | VANDA PHARMACEUTICALS INC | $0 | – | -158,700 | -100.0% | -0.25% | – |
| CCXI | Exit | CHEMOCENTRYX INC | $0 | – | -68,320 | -100.0% | -0.25% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -175,152 | -100.0% | -0.28% | – |
| CUTR | Exit | CUTERA INC | $0 | – | -86,180 | -100.0% | -0.36% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -40,000 | -100.0% | -0.37% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -27,500 | -100.0% | -0.37% | – |
| DYN | Exit | DYNE THERAPEUTICS INC | $0 | – | -338,760 | -100.0% | -0.40% | – |
| BAX | Exit | BAXTER INTL INC | $0 | – | -51,000 | -100.0% | -0.44% | – |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -298,700 | -100.0% | -0.49% | – |
| GLPG | Exit | GALAPAGOS NVspon adr | $0 | – | -98,800 | -100.0% | -0.54% | – |
| BVS | Exit | BIOVENTUS INC | $0 | – | -428,397 | -100.0% | -0.62% | – |
| IWM | Exit | ISHARES TRput | $0 | – | -508,500 | -100.0% | -11.32% | – |
| XBI | Exit | SPDR SER TRput | $0 | – | -1,292,000 | -100.0% | -14.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
| IRADIMED CORP | 16 | Q3 2023 | 5.8% |
| XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
| IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
| SURMODICS INC | 14 | Q3 2023 | 4.7% |
| NATERA INC | 13 | Q3 2023 | 3.9% |
| DEXCOM INC | 13 | Q2 2023 | 4.2% |
| NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
| CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
| LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.